A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]
The Life Raft Group is excited to announce that our Virtual GIST Tumor Boards have been so successful within the global Pediatric GIST community that we are now expanding our applications to review adult GIST [...]
The Water of Life event is the first annual whisky fundraiser hosted by LRG member, Dr. Mathew J. Lurin (co-founder of the Whisky Nerds). The word whisky (or whiskey) comes from the Gaelic uisce/uisge, [...]
New steps have been taken in Chile that will benefit patients who need high cost treatments. Piga Fernández, LRG Global Consultant in Chile, together with representatives of 26 patient organizations has been working on [...]
On Wednesday, February 11, the Life Raft Group’s state leaders had their first opportunity to gather virtually and to discuss the best strategies for bringing together and building a support community for patients and [...]
I had a “surprise” diagnosis of GIST in April, 2009, and thanks to the Life Raft Group and its knowledge and an excellent surgeon along with the assistance of Gleevec for about five years, [...]
In a recent study led by Danielle A Bischof, MD of Johns Hopkins and published in JAMA Surgery, the authors propose a new way of estimating disease-free survival for GIST patients – Conditional Disease-free Survival [...]
A recent roundtable discussion at the National Comprehensive Cancer Network’s (NCCN) 20th Annual Conference opened up a discussion on treatment costs and introduced the proposed use of evidence blocks to compare treatments. Currently, the [...]
Cancer patients are surviving longer thanks to breakthrough treatments like targeted therapies. With the additional longevity, however, is the responsibility to consider other health issues that may manifest, either due to treatments such as [...]
A Phase II clinical trial comparing Imatinib alternated with Regorafenib to Imatinib alone is currently underway and recruiting in Australia. The trial, sponsored by the Australasian Gastro-Intestinal Trials Group, looks to examine the feasibility of [...]
